Evidence map›Paper›PMID 40040312›Full record

SynthesisCPT: pharmacometrics & systems pharmacology2025

Postmarketing Assessment of Antibody-Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach.

Innocent Gerald Asiimwe, Nour Chtiba, Samer Mouksassi, Goonaseelan Colin Pillai, Raimund M Peter, Eunice Yuen, Venkatesh Pilla Reddy

Abstract readMeta-Analysis
In one paragraph

Synthesis in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Innocent Gerald AsiimweThe Wolfson Centre for Personalized Medicine, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID https://orcid.org/0000-0002-1196-1822
Nour ChtibaPharmacy of Monastir, University of Monastir, Monastir, Tunisia.
Samer MouksassiCertara, Cairo, Egypt.ORCID https://orcid.org/0000-0002-7152-6654
Goonaseelan Colin PillaiAPT-Africa Fellowship Program, c/o Pharmacometrics Africa NPC, Groote Schuur Hospital, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-5658-3837
Raimund M PeterGlobal PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK.ORCID https://orcid.org/0009-0005-7175-0858
Eunice YuenGlobal PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK.ORCID https://orcid.org/0000-0003-2145-6368
Venkatesh Pilla ReddyGlobal PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK.ORCID https://orcid.org/0000-0002-7786-4371

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) are a promising class of targeted cancer therapies. However, they need careful dose optimization to maximize effectiveness and minimize side effects. Sometimes, safety issues may only become apparent after approval, so ongoing evaluation is important. This study aimed to assess the benefit-risk profiles of two approved trastuzumab-drug conjugates: trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd). A systematic search of MEDLINE on May 1, 2024, identified clinical trials reporting the pharmacokinetics, pharmacodynamics, safety, and efficacy of T-DM1 and T-DXd. Summary-level data from 103 trials was used along with model-based meta-analysis to develop population pharmacokinetic and exposure-response models for both ADCs. The study combined the objective response rate (ORR) and dose-limiting toxicity (DLT) into a composite score called the clinical utility index (CUI) to determine optimal drug exposures and doses that maximize the benefit-risk balance. Different ORR/DLT weights and CUI thresholds representing desired minimum effect size were tested in three scenarios ("only phase I trials," "phase I/II trials," and "all phases"). Using a CUI threshold of 10%, the approved T-DM1 dose of 3.6 mg/kg for breast cancer was found to align with an efficacy-safety (ORR-DLT) ratio of 81:19 with all phases. Applying these weights to the T-DXd analyses successfully predicted the approved T-DXd dose (5.4 mg/kg, breast cancer), showing a CUI improvement compared to the 3.2 mg/kg dose of 8.3%, 8.2%, and 2.4% in the three respective scenarios. Overall, this proof-of-concept assessment of ADCs can save time and costs for pharmaceutical companies and optimize dosing to maximize patient benefit.

Indexed as

Ado-Trastuzumab EmtansineAntineoplastic Agents, ImmunologicalImmunoconjugatesTrastuzumabBreast NeoplasmsCamptothecinDose-Response Relationship, DrugHumansModels, BiologicalProduct Surveillance, PostmarketingProof of Concept StudyAdo-Trastuzumab EmtansineAntineoplastic Agents, ImmunologicalCamptothecinImmunoconjugatesTrastuzumabtrastuzumab deruxtecanantibody–drug conjugatesclinical utility indexmodel‐based meta‐analysistrastuzumab deruxtecantrastuzumab emtansine

Identifiers

PMID40040312
PMCPMC12625083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.